In a paper published online in the journal Radiology, Dr Dow-Mu Koh, Professor Martin Leach and Professor Val Lewington claim that dynamic contrast enhanced (DCE-) MRI can be used to monitor and predict response to this therapy.
What does DCE stand for?
DCE stands for Dynamic Contrast Enhanced (medical tests)
This definition appears very rarely and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of DCE
We have 177 other meanings of DCE in our Acronym Attic
- Doppler Compensation Enabled
- Dossier de Consultation des Entreprises
- Droplet Combustion Experiment
- Drum Corps Europe
- Dual Cycle Ergometer
- Duke Corporate Education (est. 2000)
- Dutch Caribbean Airline (Netherlands Antilles, ICAO code)
- Dynamic Channel Equalizer
- Dynamic Clergy Europe
- Dynamic Collaborative Environment
- Distributed Computing Environment/Remote Procedure Call
- Disaster Coordinating Element/Medical Task Force (FEMA)
- Distributed Computing Environment/Remote Procedure Call (also abbreviated DCERPC)
- Domestic Cannabis Eradication And Suppression Program
- Dade County Expressway Authority (Florida)
- Danish Centre for Environmental Assessment (Aalborg University; Denmark)
- Data Center Environment Assessment
- Denver City Energy Associates LP (Denver City, TX)
- Digital Control Electronics Assembly
- División de Ciencias Económico Administrativas (Spanish: Economic and Administrative Sciences Division; Mexico)
Samples in periodicals archive:
The Company also reported that certain patients with N-cadherin positive tumors displayed evidence of vascular effects in their tumors, such as changes in blood flow, as assessed by dynamic contrast enhanced MRI (DCE-MRI), and that the drug showed pharmacology properties that would support further clinical development.
These studies, which include both standard CT tumor imaging and dynamic contrast enhanced MRI (DCE-MRI), an advanced imaging technique for directly measuring blood flow and vascular permeability in tumors, were awarded to VirtualScopics on the strength of the company's performance on two earlier Phase I trials of the same compound.